CEO Jeremy Skillington, Poolbeg Pharma (LON: POLB) Interview
Share Talk caught up with our CEO to discuss yesterday\u2019s announcement on POLB\u2019s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full licence and collaboration agreement to follow. to develop an oral vaccine delivery platform as well as some other recently announced developments & the future of vaccines.
\n
\nJeremy Skillington, PhD, CEO of Poolbeg Pharma, said: \u201cAs we have seen in the COVID-19 pandemic, the success of global vaccination drives is dependent on the effective uptake of vaccines. Oral vaccines are highly attractive due to their improved stability profiles, ease of administration, generation of mucosal immunity and being preferable to needle-phobic patients.
\n
\n\n\n\u201cThe pharma sector is increasingly recognising that oral vaccines can act as standalone regimens or as boosters to injected vaccines which can struggle to generate mucosal immunity. By working with the experts at AnaBio and accessing its advanced micro and nano encapsulation technology, this places Poolbeg in a prime position to develop products for the oral vaccine market with vaccines for enteric (gut) and respiratory pathogens.\u201d
\n
\nhttps://www.share-talk.com/share-talk-catches-up-with-ceo-jeremy-skillington-poolbeg-pharma-lon-polb-interview/\n